1,095 Shares in Danaher Co. (NYSE:DHR) Acquired by OneAscent Financial Services LLC

OneAscent Financial Services LLC purchased a new stake in Danaher Co. (NYSE:DHR) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,095 shares of the conglomerate’s stock, valued at approximately $251,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Cynosure Group LLC boosted its stake in Danaher by 449.5% during the fourth quarter. Cynosure Group LLC now owns 9,512 shares of the conglomerate’s stock worth $2,183,000 after acquiring an additional 7,781 shares in the last quarter. Bryce Point Capital LLC acquired a new position in shares of Danaher during the fourth quarter valued at about $491,000. Massachusetts Financial Services Co. MA boosted its position in shares of Danaher by 2.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,679,156 shares of the conglomerate’s stock worth $844,550,000 after purchasing an additional 96,174 shares in the last quarter. RFG Bristol Wealth Advisors LLC acquired a new stake in shares of Danaher in the 4th quarter valued at about $1,143,000. Finally, Weitz Investment Management Inc. increased its position in Danaher by 14.9% in the 4th quarter. Weitz Investment Management Inc. now owns 403,210 shares of the conglomerate’s stock valued at $92,557,000 after buying an additional 52,300 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Down 8.3 %

NYSE DHR opened at $181.42 on Friday. The stock has a market capitalization of $129.66 billion, a price-to-earnings ratio of 34.36, a PEG ratio of 2.66 and a beta of 0.86. The business’s fifty day moving average is $209.99 and its 200-day moving average is $234.26. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a one year low of $181.20 and a one year high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the business earned $2.09 EPS. Equities research analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.32 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Friday, March 28th. Danaher’s dividend payout ratio (DPR) is currently 24.24%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on DHR shares. Scotiabank assumed coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. Wells Fargo & Company cut their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. The Goldman Sachs Group upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price target for the company in a research note on Friday, March 21st. Jefferies Financial Group dropped their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $278.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.